Rosuvastatin: A Review of the Pharmacology and Clinical Effectiveness in Cardiovascular Disease
| Autor: | Alistair S. Hall, Julian H. Barth, Ahai Luvai, Wycliffe Mbagaya |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2012 |
| Předmět: |
cardiovascular risk
lcsh:Diseases of the circulatory (Cardiovascular) system Evidence-based practice business.industry Clinical effectiveness MEDLINE nutritional and metabolic diseases Pharmacy Disease Pharmacology statins low density lipoprotein cholesterol Clinical trial lcsh:RC666-701 Informatics Medicine Rosuvastatin Cardiology and Cardiovascular Medicine business Expert Review rosuvastatin medicine.drug |
| Zdroj: | Clinical Medicine Insights. Cardiology Clinical Medicine Insights: Cardiology, Vol 6 (2012) Clinical Medicine Insights: Cardiology, Vol 2012, Iss 6, Pp 17-33 (2012) |
| ISSN: | 1179-5468 |
| Popis: | Rosuvastatin is a new generation HMG-CoA reductase inhibitor which exhibits some unique pharmacologic and pharmacokinetic properties. It has low extrahepatic tissue penetration, low potential for CYP3A4 interactions and substantial LDL-C lowering capacity and therefore has distinct advantages. We conducted a Medline literature search to identify rosuvastatin papers published in English. In this review, we outline the pharmacology of rosuvastatin, highlighting its efficacy and safety. We also review the major clinical trials with reference to primary and secondary prevention, familial hypercholesterolaemia and comparison with other statins. Finally we address its place in clinical practice. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|